Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Clinical Trial ID NCT01044069

PubWeight™ 52.05‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01044069

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013 7.99
2 Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011 7.49
3 Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014 5.60
4 Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010 3.57
5 The basic principles of chimeric antigen receptor design. Cancer Discov 2013 3.28
6 Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014 2.84
7 Gene-engineered T cells for cancer therapy. Nat Rev Cancer 2013 2.07
8 Chimeric antigen receptor therapy for cancer. Annu Rev Med 2013 1.94
9 Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013 1.91
10 Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 2013 1.64
11 CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS One 2013 1.19
12 Engineered T-cell therapy shows efficacy in blood cancer. Nat Biotechnol 2011 1.17
13 Driving CAR T-cells forward. Nat Rev Clin Oncol 2016 1.09
14 Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med 2010 0.99
15 Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol 2013 0.98
16 Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies. Cancer Gene Ther 2015 0.97
17 CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol 2015 0.95
18 Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 2014 0.89
19 Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia 2014 0.86
20 Clinical development of gene therapy: results and lessons from recent successes. Mol Ther Methods Clin Dev 2016 0.85
21 Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol 2015 0.84
22 Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol 2012 0.84
23 Genetically engineered T cells for the treatment of cancer. J Intern Med 2013 0.83
24 Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol 2011 0.79
25 Cellular therapies in acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2011 0.78
26 Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. World J Stem Cells 2015 0.78
27 Using gene therapy to manipulate the immune system in the fight against B-cell leukemias. Expert Opin Biol Ther 2015 0.77
28 Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer 2015 0.75
Next 100